None listed
Conditions
Brief summary
Blepharitis treatment represents a key issue common to many chronic diseases that rely on over the counter treatment and prevention, namely the limited efficacy and range of available treatment options. Whilst often undiagnosed and unrecognised by the general public, many chronic blepharitis patients are markedly debilitated by their symptoms, struggling to perform visually reliant, day-to-day tasks such as reading or driving. A 2012 review found no cure for blepharitis with the majority of treatments marketed to patients without sufficient evidence. This pilot study aims to investigate Honevo (10% glycerine/90% Kanuka) as an alternative, acceptable treatment for blepharitis. The results of this study will be used to decide whether or not to pursue larger, efficacy based trials for the use of Honevo in blepharitis.
Interventions
Honevo, which is topical medical grade Kanuka honey (10% glycerine and 90% Kanuka honey) is liberally applied to the affected eyelid margins once per day at night for 60 seconds for a period of twenty eight days. A participant ediary will record applications every four days during this period.
Sponsors
Honeylab Ltd
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator)
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Equal to or greater than 16 years old at the time of enrolment. Optometrist diagnosis of current chronic blepharitis.
Exclusion criteria
Requirement of any topical or systemic antibiotic for any ophthalmic indication. Requirement of any topical or systemic corticosteroid for any ophthalmic indication. Use of any systemic corticosteroid or antibiotic for any indication during the 14 days prior to enrolment. Known or suspected allergy to honey, bees, glycerine, Sterilid (Registered Trademark) or Tea tree oil. Any condition or issue which, at the investigators discretion may pose a safety risk or impact the validity of the study results. Ocular surgery within the last 3 months or planned during the following 3 months. Pregnant or breastfeeding.
Outcome results
None listed